Cedar Mountain Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Cedar Mountain Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-573	Closed	-$9K	–	324
2023 Q2	$9K	Hold	573	–	–	﹤0.01%	174
2023 Q1	$9.44K	Hold	573	–	–	﹤0.01%	168
2022 Q4	$8.94K	Hold	573	–	–	﹤0.01%	169
2022 Q3	$7K	Hold	573	–	–	﹤0.01%	190
2022 Q2	$8K	Hold	573	–	–	﹤0.01%	183
2022 Q1	$8K	Hold	573	–	–	﹤0.01%	202
2021 Q4	$8K	Hold	573	–	–	﹤0.01%	199
2021 Q3	$9K	Hold	573	–	–	﹤0.01%	180
2021 Q2	$10K	Hold	573	–	–	﹤0.01%	168
2021 Q1	$10K	Hold	573	–	–	﹤0.01%	177
2020 Q4	$10K	Hold	573	–	–	﹤0.01%	176
2020 Q3	$10K	Hold	573	–	–	﹤0.01%	163
2020 Q2	$10K	Hold	573	–	–	﹤0.01%	155
2020 Q1	$9K	Hold	573	–	–	﹤0.01%	130
2019 Q4	$11K	Buy	+573	New	+$11K	﹤0.01%	137

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cedar Mountain Advisors's TAK Position: Q3 2023 in Review

Cedar Mountain Advisors sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 573 shares — an estimated $9K sold.

Cedar Mountain Advisors first reported a position in TAK in Q4 2019 and held it in 15 quarters. The position peaked at $11K in Q4 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Cedar Mountain Advisors reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Cedar Mountain Advisors sold 573 Takeda Pharmaceutical shares in Q3 2023, an estimated $9K.
Cedar Mountain Advisors first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 15 quarters.
Cedar Mountain Advisors's Takeda Pharmaceutical position peaked at $11K in Q4 2019.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Cedar Mountain Advisors's 13F filing for Q3 2023, filed 23 Oct 2023.